Catalent (NYSE:CTLT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, January 18th.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other analysts have also issued reports about the company. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. First Analysis started coverage on Catalent in a research note on Friday, January 5th. They issued an “equal weight” rating on the stock. Royal Bank of Canada started coverage on Catalent in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $46.00 price target on the stock. Finally, Piper Jaffray Companies lifted their price target on Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 7th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Catalent has an average rating of “Buy” and an average price target of $45.60.
Shares of Catalent (NYSE:CTLT) traded down $0.11 during mid-day trading on Thursday, reaching $40.47. The company had a trading volume of 1,298,233 shares, compared to its average volume of 1,020,925. The company has a debt-to-equity ratio of 2.66, a quick ratio of 2.49 and a current ratio of 2.22. The stock has a market capitalization of $5,395.42, a PE ratio of 71.00, a P/E/G ratio of 2.32 and a beta of 1.47. Catalent has a 52 week low of $27.48 and a 52 week high of $47.87.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The company had revenue of $606.30 million during the quarter, compared to analysts’ expectations of $565.05 million. During the same period last year, the business earned $0.27 earnings per share. Catalent’s quarterly revenue was up 25.3% on a year-over-year basis. research analysts anticipate that Catalent will post 1.53 EPS for the current year.
In other Catalent news, Director Uwe Roehrhoff bought 7,500 shares of Catalent stock in a transaction on Tuesday, November 21st. The shares were bought at an average price of $39.22 per share, for a total transaction of $294,150.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
Several hedge funds have recently bought and sold shares of CTLT. Zions Bancorporation purchased a new stake in shares of Catalent in the 3rd quarter valued at $100,000. Acrospire Investment Management LLC raised its holdings in shares of Catalent by 72.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares during the period. Quantbot Technologies LP raised its holdings in shares of Catalent by 110.7% in the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after buying an additional 1,804 shares during the period. First Bank & Trust raised its holdings in shares of Catalent by 54.2% in the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after buying an additional 1,323 shares during the period. Finally, Fortaleza Asset Management Inc. purchased a new stake in shares of Catalent in the 3rd quarter valued at $164,000. Hedge funds and other institutional investors own 98.86% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Catalent (CTLT) Downgraded by Zacks Investment Research to “Hold”” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://ledgergazette.com/2018/02/12/zacks-investment-research-downgrades-catalent-ctlt-to-hold.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.